$Capricor疗法(CAPR)$ 太猛了。真是出早了，1.25就跑了。关键是觉得“Under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product.”在叠加在Ophan drug之上时，似乎并没有什么用处，完全不值得涨这么多。加上一个刚刚file的424B3，更让人觉得涨不上去。

小药股想要准确估值，以及评估investor sentiment，真的是件不可能任务。